

ForPatients

by Roche

Pancreatic Ductal Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC) Gastric Cancer
Metastatic Solid Tumors Non Small Cell Lung Carcinoma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status

Active, not recruiting

Trial Runs In

10 Countries

Trial Identifier

NCT05867121 2022-502615-11-00
GO44010

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

Genentech, Inc.

Sponsor

Phase 1

Phase

NCT05867121 2022-502615-11-00 GO44010

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No